AWKN — Awakn Life Sciences Share Price
- CA$5.10m
- CA$4.98m
- CA$0.09m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 53.1 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | -3648.2% |
Financial Summary
Year End 31st Jan | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CA$m | n/a | n/a | 0.24 | n/a | 0.09 | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Awakn Life Sciences Corp. is a Canada-based biotechnology company. The Company is engaged in the research, development, and commercializing of therapeutics to treat addiction with a focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company operates through three segments: development, delivery and corporate. The development segment, which focuses on researching and developing psychedelic drugs and therapies, ketamine-assisted psychotherapy and methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy to treat substance and behavioral addictions. The delivery segment, which includes a chain of medical psychedelic clinics across Europe. The Company operates in the United Kingdom (UK), Ireland and Canada.
Directors
- Last Annual
- January 31st, 2024
- Last Interim
- April 30th, 2024
- Incorporated
- June 21st, 2018
- Public Since
- June 23rd, 2021
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 40,805,481
- Address
- 301-217 Queen St West, TORONTO, M5V 0R2
- Web
- https://awaknlifesciences.com/
- Phone
- +1 4169075644
- Contact
- Anthony Tennyson
- Auditors
- MNP LLP
Similar to AWKN
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Alpha Cognition
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
BetterLife Pharma
Canadian Securities Exchange
FAQ
As of Today at 19:28 UTC, shares in Awakn Life Sciences are trading at CA$0.13. This share price information is delayed by 15 minutes.
Shares in Awakn Life Sciences last closed at CA$0.13 and the price had moved by over the past 365 days. In terms of relative price strength the Awakn Life Sciences share price has matched the Toronto Stock Exchange 300 Composite Index by over the past year.
There is no consensus recommendation for this security.
Find out moreAwakn Life Sciences does not currently pay a dividend.
Awakn Life Sciences does not currently pay a dividend.
Awakn Life Sciences does not currently pay a dividend.
To buy shares in Awakn Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.13, shares in Awakn Life Sciences had a market capitalisation of CA$5.10m.
Here are the trading details for Awakn Life Sciences:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: AWKN
Based on an overall assessment of its quality, value and momentum Awakn Life Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Awakn Life Sciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -4.44%.
As of the last closing price of CA$0.13, shares in Awakn Life Sciences were trading -6.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Awakn Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Awakn Life Sciences' directors